SG11201804993RA - Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes - Google Patents

Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes

Info

Publication number
SG11201804993RA
SG11201804993RA SG11201804993RA SG11201804993RA SG11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA
Authority
SG
Singapore
Prior art keywords
sanofi
frankfurt
international
aventis
main
Prior art date
Application number
SG11201804993RA
Other languages
English (en)
Inventor
Torsten Haack
Oliver Plettenburg
Andreas Evers
Michael Wagner
Martin Bossart
Romain Bertrand
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201804993RA publication Critical patent/SG11201804993RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201804993RA 2015-12-14 2016-12-12 Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes SG11201804993RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15307000 2015-12-14
PCT/EP2016/080553 WO2017102613A1 (fr) 2015-12-14 2016-12-12 Agonistes des récepteurs du glucagon sélectifs comprenant un fragment chélatant à des fins d'imagerie

Publications (1)

Publication Number Publication Date
SG11201804993RA true SG11201804993RA (en) 2018-07-30

Family

ID=55129466

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804993RA SG11201804993RA (en) 2015-12-14 2016-12-12 Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes

Country Status (21)

Country Link
US (1) US11046743B2 (fr)
EP (1) EP3389697B1 (fr)
JP (1) JP6986516B2 (fr)
KR (1) KR20180086270A (fr)
CN (1) CN108697767B (fr)
AU (1) AU2016372245B2 (fr)
BR (1) BR112018011892A2 (fr)
CA (1) CA3008052C (fr)
DK (1) DK3389697T3 (fr)
ES (1) ES2846023T3 (fr)
HR (1) HRP20210073T1 (fr)
HU (1) HUE053079T2 (fr)
IL (1) IL259961A (fr)
LT (1) LT3389697T (fr)
MX (1) MX2018007323A (fr)
PL (1) PL3389697T3 (fr)
PT (1) PT3389697T (fr)
RU (1) RU2018125958A (fr)
SG (1) SG11201804993RA (fr)
SI (1) SI3389697T1 (fr)
WO (1) WO2017102613A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
CN101282991A (zh) * 2005-05-26 2008-10-08 布里斯托尔-迈尔斯斯奎布公司 N-端修饰的胰高血糖素样肽-1受体调节剂
WO2007139589A1 (fr) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Modulateurs des récepteurs de glp-1 à libération prolongée
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104870009B (zh) * 2012-12-21 2021-05-18 赛诺菲 官能化的毒蜥外泌肽-4衍生物
US9932381B2 (en) * 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists

Also Published As

Publication number Publication date
HRP20210073T1 (hr) 2021-04-30
EP3389697B1 (fr) 2020-12-16
PL3389697T3 (pl) 2021-04-19
JP2019508480A (ja) 2019-03-28
ES2846023T3 (es) 2021-07-28
SI3389697T1 (sl) 2021-02-26
WO2017102613A1 (fr) 2017-06-22
AU2016372245B2 (en) 2020-07-16
LT3389697T (lt) 2021-02-10
CN108697767A (zh) 2018-10-23
RU2018125958A3 (fr) 2020-06-09
CA3008052A1 (fr) 2017-06-22
PT3389697T (pt) 2021-01-22
DK3389697T3 (da) 2021-01-11
US20200262885A1 (en) 2020-08-20
US11046743B2 (en) 2021-06-29
BR112018011892A2 (pt) 2018-12-04
RU2018125958A (ru) 2020-01-20
CA3008052C (fr) 2024-01-02
HUE053079T2 (hu) 2021-06-28
CN108697767B (zh) 2022-04-15
MX2018007323A (es) 2019-01-10
IL259961A (en) 2018-07-31
KR20180086270A (ko) 2018-07-30
JP6986516B2 (ja) 2021-12-22
AU2016372245A1 (en) 2018-07-26
EP3389697A1 (fr) 2018-10-24

Similar Documents

Publication Publication Date Title
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201900501RA (en) Cannabis composition
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201909520VA (en) Rna for treatment of autoimmune diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201408051VA (en) Cho expression system
SG11201809341PA (en) Mobile robot
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201804770QA (en) Method and arrangement for recovery of salt
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201903427UA (en) Deodorizing agent comprising zinc neodecanoate
SG11201906682YA (en) Glucagon receptor binding proteins and methods of use thereof